Litcius/Paper detail

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

Athena Philis‐Tsimikas, Richard M. Bergenstal, Timothy S. Bailey, Hideaki Jinnouchi, James Thrasher, Liza L. Ilag, J. Mitra, Kristen Syring, Rebecca Threlkeld

2025The Lancet22 citationsDOI

Topics & Concepts

Insulin degludecBasal insulinMedicineInsulinType 2 diabetesDiabetes mellitusInternal medicineBasal (medicine)EndocrinologyDiabetes Management and ResearchDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patients
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial | Litcius